The invention relates to a diagnostic assay for selectively measuring levels of the 35kD form of thrombin-activatable fibrinolysis inhibitor (TAFIa or TAFIai), or a derivative or variant thereof, but not the TAFI proenzyme (TAFI) or the N-terminal activation peptide of TAFI.
This application is a U.S. national stage application under 35 U.S.C. .sctn. 371 of PCT/US03/27061, filed Aug. 29, 2003 and claims the benefit under 35 U.S.C. .sctn. 119(e) of U.S. provisional application No. 60/406,756, filed Aug. 29, 2002, which is incorporated by reference herein in its entirety.
